Molecular dynamics simulations reveal dominant-negative effects and allosteric inhibition in p53 heterotetramer with R249S mutation, suggesting implications for cancer therapies.
The tumor suppressor protein p53 is one of the most frequently mutated proteins in cancer cells and is a critical target for anticancer therapies. In the nucleus, the p53 core domain binds DNA response elements as a tetramer to regulate gene transcription. During early cancer development, mutant and wild-type p53 coexist and assemble into a heterotetramer. Experimental studies confirm that the R249S mutant exerts a dominant-negative effect on wild-type p53, but the underlying molecular mechanisms, particularly how allosteric inhibition mediates the effect, remain unclear. Here, we employed all-atom molecular dynamics simulations to investigate how the R249S mutation causes dominant-negative effects in the p53 heterotetramer. Our simulations show that the mutation drives the reorganization of interfacial interactions in the heterotetramer through multiple allosteric pathways. Interestingly, the wild-type subunit forms more stable interactions with the mutant subunit than it does with wild-type subunits to adapt to the negative effects induced by the mutation in the protein.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: